Enhancer boosts psilocin potential in psychedelic therapy to treat PTSD

Canadian company NeuroPharm Inc. files application with the U.S. Patent and Trademark Office in connection with a psychedelic therapy.


Military veterans, emergency medical services and other frontline personnel face mental health risks. KatarzynaBialasiewicz/iStock/Getty Images Plus.


A Canadian company has developed a method to enhance a psychedelic therapy for PTSD treatment. The procedure uses psilocin.

The invention by NeuroPharm Inc. reduces the breakdown of psilocin, a psychoactive substance found in so-called magic mushrooms.

As a result, the pyschedelic experience may either be extended or intensified. Also, the development could result in lower dosages.

Mydecine Innovations Group Inc., the parent company of NeuroPharm, explained all these in a media release Wednesday (October 7).

As part of the release, the firm announced that NeuroPharm has filed a provisional patent application with the U.S. Patent and Trademark Office. The application involves, among others, the enhancer that boosts the efficacy of psilocin.

“The invention covered by this exciting provisional patent filing holds great promise for the treatment of a range of psychiatric disorders,” Mydecine CEO Josh Bartch said.

Psilocin and psilocybin connection

PTSD stands for Posttraumatic Stress Disorder. It’s a mental health condition that arises after an individual experiences or witnesses a traumatic event—war, crime, a major accident, or violence, for example.

Retired military personnel formed NeuroPharm. It focuses on treatments for soldiers, and also for emergency medical services and other frontline workers.

In July 2020, Mydecine acquired the company.

In the leadup to the acquisition, a media release noted that a variety of psychedelic treatments are being developed. The treatments seek to address PTSD, depression, addiction, anxiety, panic disorders, migraine, and cluster headaches.

The therapies employ psilocybin, a psychedelic substance found in magic mushrooms.

The release explained that after psilocybin is ingested, it is “rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain”.

To clarify, serotonin works as a neurotransmitter in the brain. Specifically, the substance plays a role in mood regulation.

In connection with psilocybin and psilocin, Health Canada explains online that these are the active ingredients in magic mushrooms.

The country’s drug laws prohibit the sale, possession, and production of these substances.

In addition, Health Canada notes that psilocybin and psilocin are hallucinogens that produce effects similar to LSD.

Known on the street as acid, LSD stands for lysergic acid diethylamide.

Psilocin benefits PTSD therapy

In the October 7 media release, Mydecine’s Bartch cited the benefits of the method enhancing psilocin for PTSD therapy.

“By reducing the enzymatic breakdown of psilocin, we may be able to enhance the therapeutic efficacy of psilocybin at lower dosages,” Bartch said.

Moreover, a dose reduction could lead to an “enhanced psychedelic experience, limiting non-therapeutic impacts and lower costs of administration”, the company CEO added.

“This helps to advance our mission to develop and bring to market treatments addressing a range of mental health conditions including PTSD, depression and anxiety,” Bartch said.

Mydecine’s stock, meanwhile, was trading $0.30 at the Canadian Securities Exchange on Thursday (October 8).

Follow Carlito Pablo on Twitter at @carlitopablo

Leave your opinion for the editor...We read everything!

Your email address will not be published.